Clinical implementation of 4-dihydroxyborylphenylalanine synthesised by an asymmetric pathway

Author： Kulvik M.   Vahatalo J.   Buchar E.   Farkkila M.   Jarviluoma E.   Jaaskelainen J.   Kriz O.   Laakso J.   Rasilainen M.   Ruokonen I.   Kallio M.  

Publisher： Elsevier

ISSN： 0928-0987

Source： European Journal of Pharmaceutical Sciences, Vol.18, Iss.2, 2003-02, pp. : 155-163

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Implementation of pharmacogenetics in clinical practice is challenging

By van Schie Rianne MF   de Boer Anthonius   Maitland-van der Zee Anke Hilse  

Pharmacogenomics, Vol. 12, Iss. 9, 2011-09 ,pp. : 1231-1233

Future Medicine

Access to resources Recommend Favorite

Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches

By  

Current Medicinal Chemistry, Vol. 22, Iss. 24, 2015-01 ,pp. : 2871-2901

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical pathway a road to reduced hospital admissions

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Current Status of the Implementation of Good Clinical Practice in China

By Cao Cai  

International Journal of Pharmaceutical Medicine, Vol. 20, Iss. 6, 2006-01 ,pp. : 361-366

Adis International

Access to resources Recommend Favorite

Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation

By Ong Frank S   Deignan Joshua L   Kuo Jane Z   Bernstein Kenneth E   Rotter Jerome I   Grody Wayne W   Das Kingshuk  

Pharmacogenomics, Vol. 13, Iss. 4, 2012-03 ,pp. : 465-475

Future Medicine

Access to resources Recommend Favorite